The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Telix joins Thera4Care to test FAP-targeting therapy with terbium-161

Nov 5, 2026 05:30 (2h ago)

Verifying

Telix joined Thera4Care and contributed its FAP-targeting dimer for clinical evaluation.
Thera4Care includes 27 partners and will study the candidate with terbium-161.
The Phase 1 trial initially targets ovarian, pancreatic and sarcoma patients with metastatic tumors.